Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Core Viewpoint - Athira Pharma announced transformative transactions in a press release, which were discussed during the conference call [2][3]. Group 1: Company Overview - The conference call featured key executives including Dr. Mark Litton (President and CEO), Dr. Javier San Martin (Chief Medical Officer), Dr. Kevin Church (Chief Scientific Officer), Robert Renninger (Chief Financial Officer), and Dr. David Portman (Founder and CEO of Sermonix) [2]. Group 2: Financial and Operational Insights - The call included forward-looking statements regarding the company's future clinical development activities, financial condition, and operating performance, which are based on management's current beliefs and expectations [4].